Mitchell Schnall to continue as ECOG-ACRIN Cancer Research Group co-chair

DeepHealth, TeraRecon announce collaboration around integrated AI and advanced visualization

DeepHealth and ConcertAI’s TeraRecon announced a strategic collaboration to integrate certain capabilities to advance imaging tools and the radiology workflow.

February 28, 2025

Vol.51 No.08

Guest Editorial

From the chairs of ECOG-ACRIN: A perspective on indirect costs

Indirect costs are a component of a grant award that recognizes expenses for a project that, for efficiency’s sake, are aggregated across projects and divided proportionally to projects rather than explicitly charged to each project. They are influenced by location and services provided.

February 14, 2025

Vol.51 No.06

By Peter J. O'Dwyer and Mitchell D. Schnall

Clinical Roundup

Temozolomide + radiation treatment improves OS for grade 2 gliomas

Both radiation and temozolomide, a generic chemotherapy treatment in pill form, have meaningful single-modality anti-tumor activity against slow-growing, low-grade gliomas.

December 06, 2024

Vol.50 No.45

In Brief

ECOG-ACRIN, Caris collaborate on interrogating TAILORx breast cancer trial

ECOG-ACRIN Cancer Research Group and Caris Life Sciences announced a multi-year research collaboration wherein Caris is pairing its genomic, transcriptomic, and proteomic profiling, advanced artificial intelligence and machine learning algorithms with ECOG-ACRIN’s research capabilities.

October 25, 2024

Vol.50 No.40

Clinical

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

If clinical research were anything like fly fishing, the scientific question that EA3163 trial attempted to answer might be considered “the one that got away”.

Group chairs propose funding strategy to jump-start correlative studies

The National Academy of Medicine recognized the value of correlative science in publicly funded clinical trials in 2010, recommending “the incorporation of innovative science into cancer clinical trials through the support and use of biorepositories.”

September 20, 2024

Vol.50 No.35

By Peter J. O'Dwyer